Clinical burden and predictors of asthma exacerbations in patients on guideline-based steps 4-6 asthma therapy in the TENOR cohort

William Calhoun, Tmirah Haselkorn, David R. Mink, Dave P. Miller, Alejandro Dorenbaum, Robert S. Zeiger

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Background: Patients with severe or difficult-to-treat asthma on guideline-recommended Steps 4/5/6 therapy have not previously been described. Objective: To characterize patients with severe or difficult-to-treat asthma on Steps 4/5/6 therapy and assess predictors of future asthma exacerbations. Methods: Patients ages ≥12 years with baseline and month 12 medication data were assigned to Steps 4/5/6 care levels from the 2007 National Heart, Lung, and Blood Institute guidelines. Demographic, atopic, and clinical characteristics at baseline and month 12 were assessed by using descriptive statistics. Asthma-related quality of life was assessed by using the Mini Asthma Quality of Life Questionnaire, and work and activity impairment was assessed by the Work Productivity and Activity Impairment Questionnaire-Asthma. Odds ratios (OR) and 95% CI for asthma exacerbation risk at month 12 were generated by using multivariable logistic regression. Results: A total of 1186 patients were included. More than two-thirds of the patients (67.4%) were on ≥3 long-term controllers, and 55.1% were considered difficult to treat due to frequent exacerbations. Patients reported low asthma-related quality of life scores and considerable impairment in overall work and daily activity (21.4% and 32.1%, respectively). After adjustment for covariates, exacerbation history (hospitalization, OR 6.27 [95% CI, 3.61-10.88]; emergency department visit, OR 3.84 [95% CI, 2.50-5.91]; corticosteroid burst, OR 2.89 [95% CI, 2.18-3.82]) and very poorly controlled asthma (OR 1.95 [95% CI, 1.41-2.71] vs not well controlled) were independently associated with risk of a future exacerbation (all P < .001). Conclusion: Despite multiple long-term controller medications, patients with severe or difficult-to-treat asthma on Steps 4/5/6 therapy present with significant clinical burden and risk of future asthma exacerbations.

Original languageEnglish (US)
JournalJournal of Allergy and Clinical Immunology: In Practice
Volume2
Issue number2
DOIs
StatePublished - 2014

Fingerprint

Asthma
Guidelines
Odds Ratio
Therapeutics
Quality of Life
National Heart, Lung, and Blood Institute (U.S.)
Hospital Emergency Service
Adrenal Cortex Hormones
Hospitalization
Logistic Models
History
Demography

Keywords

  • Anti-asthmatic agents
  • Asthma guidelines
  • Asthma therapy
  • Exacerbations
  • Severe or difficult-to-treat asthma
  • Uncontrolled asthma

ASJC Scopus subject areas

  • Immunology and Allergy

Cite this

Clinical burden and predictors of asthma exacerbations in patients on guideline-based steps 4-6 asthma therapy in the TENOR cohort. / Calhoun, William; Haselkorn, Tmirah; Mink, David R.; Miller, Dave P.; Dorenbaum, Alejandro; Zeiger, Robert S.

In: Journal of Allergy and Clinical Immunology: In Practice, Vol. 2, No. 2, 2014.

Research output: Contribution to journalArticle

@article{3e718e402c8e4be58bce6576d5c7704c,
title = "Clinical burden and predictors of asthma exacerbations in patients on guideline-based steps 4-6 asthma therapy in the TENOR cohort",
abstract = "Background: Patients with severe or difficult-to-treat asthma on guideline-recommended Steps 4/5/6 therapy have not previously been described. Objective: To characterize patients with severe or difficult-to-treat asthma on Steps 4/5/6 therapy and assess predictors of future asthma exacerbations. Methods: Patients ages ≥12 years with baseline and month 12 medication data were assigned to Steps 4/5/6 care levels from the 2007 National Heart, Lung, and Blood Institute guidelines. Demographic, atopic, and clinical characteristics at baseline and month 12 were assessed by using descriptive statistics. Asthma-related quality of life was assessed by using the Mini Asthma Quality of Life Questionnaire, and work and activity impairment was assessed by the Work Productivity and Activity Impairment Questionnaire-Asthma. Odds ratios (OR) and 95{\%} CI for asthma exacerbation risk at month 12 were generated by using multivariable logistic regression. Results: A total of 1186 patients were included. More than two-thirds of the patients (67.4{\%}) were on ≥3 long-term controllers, and 55.1{\%} were considered difficult to treat due to frequent exacerbations. Patients reported low asthma-related quality of life scores and considerable impairment in overall work and daily activity (21.4{\%} and 32.1{\%}, respectively). After adjustment for covariates, exacerbation history (hospitalization, OR 6.27 [95{\%} CI, 3.61-10.88]; emergency department visit, OR 3.84 [95{\%} CI, 2.50-5.91]; corticosteroid burst, OR 2.89 [95{\%} CI, 2.18-3.82]) and very poorly controlled asthma (OR 1.95 [95{\%} CI, 1.41-2.71] vs not well controlled) were independently associated with risk of a future exacerbation (all P < .001). Conclusion: Despite multiple long-term controller medications, patients with severe or difficult-to-treat asthma on Steps 4/5/6 therapy present with significant clinical burden and risk of future asthma exacerbations.",
keywords = "Anti-asthmatic agents, Asthma guidelines, Asthma therapy, Exacerbations, Severe or difficult-to-treat asthma, Uncontrolled asthma",
author = "William Calhoun and Tmirah Haselkorn and Mink, {David R.} and Miller, {Dave P.} and Alejandro Dorenbaum and Zeiger, {Robert S.}",
year = "2014",
doi = "10.1016/j.jaip.2013.11.013",
language = "English (US)",
volume = "2",
journal = "Journal of Allergy and Clinical Immunology: In Practice",
issn = "2213-2198",
publisher = "Elsevier",
number = "2",

}

TY - JOUR

T1 - Clinical burden and predictors of asthma exacerbations in patients on guideline-based steps 4-6 asthma therapy in the TENOR cohort

AU - Calhoun, William

AU - Haselkorn, Tmirah

AU - Mink, David R.

AU - Miller, Dave P.

AU - Dorenbaum, Alejandro

AU - Zeiger, Robert S.

PY - 2014

Y1 - 2014

N2 - Background: Patients with severe or difficult-to-treat asthma on guideline-recommended Steps 4/5/6 therapy have not previously been described. Objective: To characterize patients with severe or difficult-to-treat asthma on Steps 4/5/6 therapy and assess predictors of future asthma exacerbations. Methods: Patients ages ≥12 years with baseline and month 12 medication data were assigned to Steps 4/5/6 care levels from the 2007 National Heart, Lung, and Blood Institute guidelines. Demographic, atopic, and clinical characteristics at baseline and month 12 were assessed by using descriptive statistics. Asthma-related quality of life was assessed by using the Mini Asthma Quality of Life Questionnaire, and work and activity impairment was assessed by the Work Productivity and Activity Impairment Questionnaire-Asthma. Odds ratios (OR) and 95% CI for asthma exacerbation risk at month 12 were generated by using multivariable logistic regression. Results: A total of 1186 patients were included. More than two-thirds of the patients (67.4%) were on ≥3 long-term controllers, and 55.1% were considered difficult to treat due to frequent exacerbations. Patients reported low asthma-related quality of life scores and considerable impairment in overall work and daily activity (21.4% and 32.1%, respectively). After adjustment for covariates, exacerbation history (hospitalization, OR 6.27 [95% CI, 3.61-10.88]; emergency department visit, OR 3.84 [95% CI, 2.50-5.91]; corticosteroid burst, OR 2.89 [95% CI, 2.18-3.82]) and very poorly controlled asthma (OR 1.95 [95% CI, 1.41-2.71] vs not well controlled) were independently associated with risk of a future exacerbation (all P < .001). Conclusion: Despite multiple long-term controller medications, patients with severe or difficult-to-treat asthma on Steps 4/5/6 therapy present with significant clinical burden and risk of future asthma exacerbations.

AB - Background: Patients with severe or difficult-to-treat asthma on guideline-recommended Steps 4/5/6 therapy have not previously been described. Objective: To characterize patients with severe or difficult-to-treat asthma on Steps 4/5/6 therapy and assess predictors of future asthma exacerbations. Methods: Patients ages ≥12 years with baseline and month 12 medication data were assigned to Steps 4/5/6 care levels from the 2007 National Heart, Lung, and Blood Institute guidelines. Demographic, atopic, and clinical characteristics at baseline and month 12 were assessed by using descriptive statistics. Asthma-related quality of life was assessed by using the Mini Asthma Quality of Life Questionnaire, and work and activity impairment was assessed by the Work Productivity and Activity Impairment Questionnaire-Asthma. Odds ratios (OR) and 95% CI for asthma exacerbation risk at month 12 were generated by using multivariable logistic regression. Results: A total of 1186 patients were included. More than two-thirds of the patients (67.4%) were on ≥3 long-term controllers, and 55.1% were considered difficult to treat due to frequent exacerbations. Patients reported low asthma-related quality of life scores and considerable impairment in overall work and daily activity (21.4% and 32.1%, respectively). After adjustment for covariates, exacerbation history (hospitalization, OR 6.27 [95% CI, 3.61-10.88]; emergency department visit, OR 3.84 [95% CI, 2.50-5.91]; corticosteroid burst, OR 2.89 [95% CI, 2.18-3.82]) and very poorly controlled asthma (OR 1.95 [95% CI, 1.41-2.71] vs not well controlled) were independently associated with risk of a future exacerbation (all P < .001). Conclusion: Despite multiple long-term controller medications, patients with severe or difficult-to-treat asthma on Steps 4/5/6 therapy present with significant clinical burden and risk of future asthma exacerbations.

KW - Anti-asthmatic agents

KW - Asthma guidelines

KW - Asthma therapy

KW - Exacerbations

KW - Severe or difficult-to-treat asthma

KW - Uncontrolled asthma

UR - http://www.scopus.com/inward/record.url?scp=84895502078&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84895502078&partnerID=8YFLogxK

U2 - 10.1016/j.jaip.2013.11.013

DO - 10.1016/j.jaip.2013.11.013

M3 - Article

C2 - 24607048

AN - SCOPUS:84895502078

VL - 2

JO - Journal of Allergy and Clinical Immunology: In Practice

JF - Journal of Allergy and Clinical Immunology: In Practice

SN - 2213-2198

IS - 2

ER -